1492 Capital Management Lowered By $839,344 Its Neogenomics (NEO) Stake; Security National Financial Has 0.46 Sentiment

December 16, 2017 - By Louis Casey

Security National Financial Corporation engages in life insurance, cemetery and mortuary, and mortgage loan businesses. The company has market cap of $79.38 million. The companyÂ’s Life Insurance segment engages in selling and servicing life insurance, annuity products, and accident and health insurance. It has a 13.33 P/E ratio. This segment offers various life insurance products, such as funeral plans and interest-sensitive life insurance; other traditional life, accident, and health insurance products; annuity products comprising single premium deferred annuities, flexible premium deferred annuities, and immediate annuities; and diver's accident policies, as well as cedes and assumes certain risks with various authorized unaffiliated reinsurers pursuant to reinsurance treaties.

1492 Capital Management Llc decreased Neogenomics Inc (NEO) stake by 21.57% reported in 2017Q2 SEC filing. 1492 Capital Management Llc sold 104,918 shares as Neogenomics Inc (NEO)’s stock declined 8.15%. The 1492 Capital Management Llc holds 381,397 shares with $3.42M value, down from 486,315 last quarter. Neogenomics Inc now has $738.16 million valuation. The stock increased 1.32% or $0.12 during the last trading session, reaching $9.18. About 651,905 shares traded or 74.71% up from the average. NeoGenomics, Inc. (NASDAQ:NEO) has declined 13.46% since December 16, 2016 and is downtrending. It has underperformed by 30.16% the S&P500.

Among 11 analysts covering NeoGenomics (NASDAQ:NEO), 9 have Buy rating, 1 Sell and 1 Hold. Therefore 82% are positive. NeoGenomics had 17 analyst reports since September 3, 2015 according to SRatingsIntel. BTIG Research downgraded the shares of NEO in report on Wednesday, July 27 to “Neutral” rating. The company was maintained on Friday, May 26 by BTIG Research. The stock of NeoGenomics, Inc. (NASDAQ:NEO) has “Buy” rating given on Friday, May 26 by Cantor Fitzgerald. The firm earned “Buy” rating on Thursday, September 3 by Roth Capital. The firm earned “Neutral” rating on Monday, September 11 by BTIG Research. Benchmark initiated the stock with “Buy” rating in Friday, March 11 report. TH Capital reinitiated it with “Buy” rating and $10.0 target in Monday, October 26 report. The stock has “Outperform” rating by William Blair on Sunday, September 6. The firm earned “Sell” rating on Wednesday, November 16 by Axiom Capital. The stock of NeoGenomics, Inc. (NASDAQ:NEO) has “Buy” rating given on Friday, May 26 by Roth Capital.

Investors sentiment increased to 1.28 in 2017 Q2. Its up 0.10, from 1.18 in 2017Q1. It increased, as 19 investors sold NEO shares while 32 reduced holdings. 17 funds opened positions while 43 raised stakes. 60.13 million shares or 3.48% more from 58.11 million shares in 2017Q1 were reported. South State Corporation holds 25,000 shares or 0.03% of its portfolio. C Gp Holdg A S holds 246,000 shares or 0.03% of its portfolio. California State Teachers Retirement accumulated 0% or 98,830 shares. Invesco Ltd accumulated 32,692 shares. 15.00M were reported by General Electr. Teton Advsr invested in 197,407 shares. Voya Investment Mgmt Limited Liability Company holds 0% or 29,333 shares. Moreover, Cadence Mngmt Ltd has 0.09% invested in NeoGenomics, Inc. (NASDAQ:NEO). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in NeoGenomics, Inc. (NASDAQ:NEO). Moreover, Finemark Retail Bank Trust has 0.26% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 403,558 shares. Emerald Advisers Inc Pa accumulated 1.25 million shares. Granahan Inv Management Inc Ma invested 0.84% in NeoGenomics, Inc. (NASDAQ:NEO). State Street holds 0% in NeoGenomics, Inc. (NASDAQ:NEO) or 999,012 shares. Scholtz & Ltd Company has 1.7% invested in NeoGenomics, Inc. (NASDAQ:NEO) for 219,500 shares. Amer Intl Group Inc Inc holds 34,611 shares.

Analysts await NeoGenomics, Inc. (NASDAQ:NEO) to report earnings on February, 28. They expect $0.03 earnings per share, 0.00% or $0.00 from last year’s $0.03 per share. NEO’s profit will be $2.41 million for 76.50 P/E if the $0.03 EPS becomes a reality. After $-0.02 actual earnings per share reported by NeoGenomics, Inc. for the previous quarter, Wall Street now forecasts -250.00% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News